She found her aunt's $900 cancer drug for 37 cents in India

When your family member gets a cancer diagnosis in the United States, the second shock arrives about three days later, once the pharmacy calls with a price. Not the diagnosis itself, not the treatment plan, not the side effects listed in a font so small it requires reading glasses. The bill. And for the people whose loved one needs a drug called Revlimid, that number tends to stop the room.

One pill. The same pill. $900 in the United States. Thirty cents in India.

That comparison has been circulating on social media, most recently in a video that crossed 905,000 views, with a comments section that reads less like a debate and more like a collective exhale from people who have been holding something in for a very long time. The Revlimid price comparison India watchers keep making in those comments is not theoretical. It is the calculation real families actually do when someone they love is diagnosed with blood cancer and handed a prescription.

What Revlimid Actually Is

Revlimid is the brand name for lenalidomide, a drug used primarily to treat multiple myeloma, a cancer of the plasma cells in bone marrow. It is not among the most common cancers, but it requires lifelong treatment in most cases. Lenalidomide works on several fronts simultaneously: it boosts the immune system, impedes the growth of malignant cells, and limits the supply of oxygen and nutrients to cancer cells.

It is also used for certain lymphomas and a group of blood disorders called myelodysplastic syndromes, a condition where bone marrow doesn’t produce enough healthy blood cells. Lenalidomide has helped thousands of multiple myeloma patients since 2005, and many patients take it for years, sometimes as maintenance therapy after a stem cell transplant.

The drug was originally developed by Celgene, a pharmaceutical company later acquired by Bristol Myers Squibb in a $74 billion deal in 2019. Celgene launched Revlimid at $215 a pill in 2005 and raised the price more than 20 times over the following years. The price has continued climbing since.

The Number That Stopped the Scroll

The video that circulated widely explained that a family member was undergoing treatment for a type of blood cancer and takes Revlimid. In the US, one pill costs $900, which is roughly ₹85,000. In contrast, generic versions in India are available for between ₹35 and ₹300 per pill, or roughly 30 cents to $3.

Revlimid pricing runs about $908 per capsule as currently paid by Medicare, while court testimony by a Celgene executive established the manufacturing cost at approximately $0.25 per capsule. There is a margin of thousands of times the manufacturing cost on lenalidomide, regardless of whether it is brand or generic.

A month’s supply at standard dosing runs branded Revlimid at over $24,000 monthly in the US, making it among the most expensive cancer drugs ever sold. US generics, though cheaper than the branded version, still cost well over $100,000 annually. The word “generic” usually promises relief. Here, it does not deliver it.

Why a Generic Already Exists in the US and Why It Doesn’t Help Much

A generic version of Bristol Myers’ Revlimid became available on the US market on March 7, 2022. Patients with multiple myeloma, a disease that often requires this drug indefinitely, might reasonably have expected that moment to change their financial picture. It mostly didn’t.

The introduction of generic Revlimid is governed by individual agreements that Bristol Myers Squibb/Celgene entered into with a number of generic companies, agreements that control exactly how much of the market those generics can actually capture. The first generic entered under volume-limited constraints, meaning only a small portion of total Revlimid demand could be met by cheaper alternatives.

Multiple manufacturers now produce generic lenalidomide in the US, with Teva being the first to launch in March 2022. Pricing remains very high, with US generics still costing over $100,000 yearly.

US patent law permits the holder of an intellectual property right to maintain exclusive pricing for a longer duration compared to countries like India, where generics can be introduced more rapidly. That structural difference accounts for a significant share of the price gap. Even for patients with insurance, American coverage is often partial. It reduces, but rarely eliminates, the out-of-pocket burden in the way that healthcare systems in Canada and India do.

India’s Pharmaceutical Position Is Not an Accident

According to India’s government press bureau, India is the largest global supplier of generic medicines, manufacturing about 60,000 generic brands across 60 therapeutic categories. India currently ranks 11th globally in pharmaceutical exports by value, with exports to 191 countries in 2024-25, of which 50 percent are directed to highly regulated markets such as the United States and Europe.

The United States, in other words, is one of India’s largest customers for generic drugs while simultaneously being a place where those same drugs cost patients a fraction of what they’d pay if they bought the Indian-made product domestically. India has the highest number of pharmaceutical manufacturing facilities compliant with US FDA standards outside the US itself, and hosts over 500 active pharmaceutical ingredient producers.

These are not substandard facilities churning out cheap imitations. They are FDA-inspected plants producing the same active molecules that end up in American pharmacies, often sold at radically different price points depending on which side of the supply chain the patient sits on.

The ibuprofen market offers a parallel worth glancing at. If you’ve ever wondered how much of what patients pay reflects the actual chemistry involved, the answer is usually: very little.

The Pricing History Nobody Advertised

The current price of Revlimid did not appear from nowhere. It was built, increase by increase, over twenty years. Celgene boosted the price of a 10-milligram dose of Revlimid by 3.5 percent to $719.82 effective January 3, 2019, on the same day the company announced its acquisition by Bristol Myers Squibb. The same dose had cost $247.28 at the end of 2007. Cancer patients need many doses of Revlimid a year, and the overall annual cost can approach $200,000.

Each of those increases was announced, processed by the industry, absorbed by insurers and patients, and then replaced by the next one. The justification offered was the cost of research, clinical trials, and regulatory approval, and those costs are real. The company invested $800 million in developing Revlimid and hundreds of millions more after it was approved by regulators in 2005. The drug did save lives.

Whether the people whose lives it saves should be expected to pay back that investment and then some, indefinitely, regardless of whether they can afford to, is a question the viral video made unavoidable.

The video has continued to circulate widely, fueling discussions around drug pricing, access to affordable medicines, and the stark differences between the healthcare systems of India and the United States. Similar accounts from American patients encountering Indian drug prices have described the experience as a window into how differently the two systems are structured.

What the Comment Section Already Knew

The video attracted more than 772,000 views and hundreds of comments, with many users echoing concerns about high drug prices in the US while others praised India’s pharmaceutical industry and the availability of lower-cost generic medicines.

One commenter noted that free cancer treatment is available at government hospitals in India. Another wrote that every time they visit India, they take the chance to buy generic medicines, also cheaper than in Europe.

The Revlimid price comparison India viewers kept making in those comments is not a theoretical exercise. It is the calculation families actually do when someone they love needs a drug that costs $900 a pill. The math on a monthly basis, at standard dosing of 30 capsules, is not something most families can absorb even with insurance covering a portion.

The Thing Nobody Wants to Say Out Loud

The price of Revlimid in the United States is not a mistake. It is not an oversight, a quirk of the market, or a temporary condition pending correction. It is the intended outcome of a system that gives pharmaceutical companies the legal tools to price without meaningful domestic competition for as long as patent protections hold, and then structures the generic entry agreements in ways that soften the competitive impact of cheaper alternatives once they do arrive.

India’s prices are not the result of India cheating or cutting corners. They are the result of a government that decided affordable medicine was a policy priority and built the regulatory framework to support it. India’s standing as the pharmacy of the world is rooted in a combination of affordable pricing and assured quality, with cost-efficient manufacturing, supported by a strong scientific workforce and scale, enabling consistent supply of essential drugs without compromising standards.

Anyone who has had a family member with cancer, multiple myeloma specifically, already knows that the American pharmaceutical pricing system operates on a logic that has very little to do with what patients can actually pay. Nine hundred dollars in the United States. Thirty cents in India. Same pill, same molecule, same manufacturer - two prices determined entirely by which system the patient lives inside.

Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.

AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.

The post Cancer Drug That Sells For $900 In America Priced For Cents In Another Country, Woman Finds appeared first on Secret Life Of Mom.